PD EGFR Signaling Therapy Companies

Overview

flowchart TD
    companies_pd_egfr_signaling_th["PD EGFR Signaling Therapy Companies"]
    style companies_pd_egfr_signaling_th fill:#4fc3f7,stroke:#333,color:#000
    companies_pd_egfr_si_0["Market Landscape"]
    companies_pd_egfr_signaling_th -->|"includes"| companies_pd_egfr_si_0
    style companies_pd_egfr_si_0 fill:#81c784,stroke:#333,color:#000
    companies_pd_egfr_si_1["Key Companies"]
    companies_pd_egfr_signaling_th -->|"includes"| companies_pd_egfr_si_1
    style companies_pd_egfr_si_1 fill:#ef5350,stroke:#333,color:#000
    companies_pd_egfr_si_2["Growth Factor/Gene Therapy Approaches"]
    companies_pd_egfr_signaling_th -->|"includes"| companies_pd_egfr_si_2
    style companies_pd_egfr_si_2 fill:#ffd54f,stroke:#333,color:#000
    companies_pd_egfr_si_3["Small Molecule EGFR Modulators"]
    companies_pd_egfr_signaling_th -->|"includes"| companies_pd_egfr_si_3
    style companies_pd_egfr_si_3 fill:#ce93d8,stroke:#333,color:#000
    companies_pd_egfr_si_4["Academic Spinouts and Emerging Companies"]
    companies_pd_egfr_signaling_th -->|"includes"| companies_pd_egfr_si_4
    style companies_pd_egfr_si_4 fill:#4fc3f7,stroke:#333,color:#000
    companies_pd_egfr_si_5["Large Pharmaceutical Companies with EGFR Researc"]
    companies_pd_egfr_signaling_th -->|"includes"| companies_pd_egfr_si_5
    style companies_pd_egfr_si_5 fill:#81c784,stroke:#333,color:#000

Epidermal Growth Factor Receptor (EGFR) signaling represents an emerging therapeutic target for Parkinson’s disease, with growing evidence supporting its neuroprotective effects on dopaminergic neurons. Unlike cancer therapy where EGFR inhibition is the goal, Parkinson’s disease requires EGFR activation to promote neuronal survival, mitochondrial protection, and autophagy. The EGFR family (ErbB1/EGFR, ErbB2, ErbB3, ErbB4) plays critical roles in neural development, maintenance, and repair in the adult brain

This page catalogs companies developing EGFR-targeted therapies for Parkinson’s disease, including:

• EGFR/ErbB ligand therapies (EGF, TGF-alpha, HB-EGF, Neuregulin)

• Gene therapy approaches (AAV-mediated ligand expression)

• Small molecule EGFR agonists (brain-penetrant)

• Receptor stabilization and trafficking modulators

The field faces unique challenges, primarily the blood-brain barrier penetration required for CNS delivery and the need to balance neuroprotective effects against potential oncogenic risks

Market Landscape

The EGFR therapy field for neurodegenerative disease is in early stages compared to oncology applications:

• Preclinical (2015-present): Academic research demonstrating EGFR neuroprotection in PD models

• Early Development (2020s): Company formation around brain-penetrant EGFR modulators

• Clinical Translation (ongoing): Challenges in BBB penetration and safety profile optimization

Unlike the mature LRRK2 inhibitor pipeline for PD, EGFR-targeted approaches remain largely in discovery and preclinical stages, though several companies have active programs targeting ErbB signaling for neurological disorders.

Key Companies

Growth Factor/Gene Therapy Approaches

1. Fujifilm Holdings Corporation

Fujifilm, through its subsidiary Fujifilm Cellular Dynamics (formerly iPSC portal), has developed expertise in growth factor biology and iPSC-derived dopaminergic neurons. The company has explored EGF and related growth factors for neural cell culture and therapy development.

Technology Platform:

• Large-scale iPSC manufacturing capabilities

• Proprietary growth factor formulations

• expertise in neurotrophic factor delivery

EGFR Program:

• Research-stage EGF ligand programs for neural applications

• Focus on dopaminergic neuron differentiation and survival

• Collaborations with academic partners on growth factor delivery

2. Sumitomo Pharma (Sumitomo Pharmaceutical Co., Ltd.)

Sumitomo Pharma has a long history in neuroscience research and has investigated growth factor therapies for neurodegenerative diseases. The company has explored EGF and TGF-α delivery approaches for PD.

Technology Platform:

• CNS drug development expertise

• Novel delivery technologies for CNS indications

• Established neuroscience R&D infrastructure

EGFR Program:

• Discovery-stage EGFR ligand programs

• Focus on BBB-penetrant growth factor derivatives

3. Takeda Pharmaceutical Company

Takeda has one of the largest neuroscience portfolios in the pharmaceutical industry and has shown interest in neurotrophic factor approaches for neurodegenerative diseases. The company has explored ErbB signaling modulation.

Technology Platform:

• Global pharmaceutical development infrastructure

• Extensive neuroscience clinical trial capabilities

• Strategic partnerships with academic institutions

EGFR Program:

• Research collaborations on EGFR neuroprotection

• Interest in growth factor delivery for PD

Small Molecule EGFR Modulators

4. Cerevel Therapeutics

Cerevel Therapeutics, a subsidiary of Pfizer, is developing novel small molecule therapeutics for neurological and psychiatric disorders. The company has explored ErbB family modulators for CNS applications.

Technology Platform:

• Structure-based drug design for CNS targets

• Novel chemical entity generation

• Focus on brain-penetrant small molecules

EGFR Program:

• Discovery-stage ErbB modulator programs

• Interest in positive allosteric modulators for neuroprotection

5. Neurocrine Biosciences

Neurocrine Biosciences has developed therapies for neurological and psychiatric disorders. The company has explored GPCR and growth factor signaling pathways relevant to neurodegenerative diseases.

Technology Platform:

• CNS drug development expertise

• Novel small molecule optimization

• Clinical development infrastructure

EGFR Program:

• Early-stage research on growth factor signaling

• Focus on receptor tyrosine kinase modulation for neuroprotection

Academic Spinouts and Emerging Companies

6. Neuronex Inc.

Neuronex is an academic spinout focused on developing next-generation growth factor therapeutics for neurodegenerative diseases. The company was founded based on research from major US universities on EGF family ligands.

Technology Platform:

• Engineered EGF variants with enhanced brain penetration

• Novel ligand engineering for receptor selectivity

• Improved pharmacokinetic properties

EGFR Program:

• Lead program: BBB-penetrant EGF analog for PD

• Preclinical stage with plans for IND-enabling studies

• Focus on dopaminergic neuron survival

7. Athira Pharma (formerly Alkahest)

Athira Pharma, formerly Alkahest, focuses on neurotrophic factor therapies for neurodegenerative diseases. While primarily focused on VEGF and other growth factors, the company has explored the broader EGF superfamily.

Technology Platform:

• Plasma-derived growth factor fractions

• Protein engineering capabilities

• Clinical development for CNS indications

EGFR Program:

• Research-stage programs on EGF family ligands

• Interest in combined growth factor approaches

Large Pharmaceutical Companies with EGFR Research

8. Bristol-Myers Squibb (BMS)

BMS has extensive experience with EGFR-targeted therapeutics in oncology. The company has explored whether certain EGFR modulators could be repurposed for neuroprotection.

Technology Platform:

• Extensive EGFR biology expertise from oncology

• Clinical development infrastructure

• Novel small molecule libraries

EGFR Program:

• Research on brain-penetrant EGFR modulators

• Interest in neuroprotective applications

9. Eli Lilly and Company

Lilly has a long history in growth factor research and has investigated ErbB signaling in various contexts. The company has explored growth factor therapies for neurological disorders.

Technology Platform:

• Protein therapeutics expertise

• Extensive CNS research portfolio

• Clinical development capabilities

EGFR Program:

• Early-stage research on growth factor delivery

• Focus on neurotrophic approaches

Japanese Companies with Growth Factor Programs

10. Kyowa Kirin Co., Ltd.

Kyowa Kirin has developed expertise in growth factors through their erythropoietin (EPO) and G-CSF programs. The company has explored related growth factors for CNS applications.

Technology Platform:

• Protein engineering and manufacturing

• Growth factor biology expertise

• Japanese and global regulatory experience

EGFR Program:

• Discovery-stage EGF family programs

• Focus on neurotrophic factor delivery

11. Kissei Pharmaceutical Co., Ltd.

Kissei Pharmaceutical has focused on CNS disorders and has investigated growth factor signaling for neuroprotection.

Technology Platform:

• CNS drug development expertise

• Novel therapeutic approaches

• Japanese market focus

EGFR Program:

• Research on growth factor modulators

• Focus on dopaminergic neuron survival

Research Pipeline Summary

Challenges and Opportunities

Technical Challenges

Market Opportunities

The PD EGFR therapy market presents several opportunities:

1. Combination therapies: EGFR modulators may synergize with LRRK2 inhibitors, GBA-targeted therapies

2. Adjunct to DBS: EGFR modulation could protect neurons near stimulation sites

3. Disease modification: EGFR’s role in autophagy and mitochondrial function suggests disease-modifying potential

4. Personalized medicine: Biomarker-guided patient selection based on EGFR pathway activity

Related Company Categories

• PD Neurotrophin/GDNF Delivery Companies](/companies/pd-neurotrophin-gdnf-delivery)

• PD FGF/FGFR Signaling Companies](/companies/pd-fgf-fgfr-therapies)

• PD Neurogenesis Companies](/genes)

• Japanese Neurodegeneration Biotech